Osemitamab (FUT8-KO)

• Description:

  Osemitamab (FUT8-KO) is an anti-claudin-18.2 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the ADCC effect of the antibody. Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].

• UNSPSC:

  12352203

• Target:

  Gap Junction Protein

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Smiles:

  [Osemitamab(FUT8-KO)]

• References & Citations:

  [1]Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002) [J]. 2023.|[2]Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  No Development Reported